



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/810,501	03/19/2001	Prem S. Paul	201503US55XD	1105	
7590 03/04/2004			EXAMINER		
Sharon E. Crane, Ph.D. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404			WORTMAN,	WORTMAN, DONNA C	
			ART UNIT	PAPER NUMBER	
Alexandria, VA 22313-1404			1648		
			DATE MAILED: 03/04/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

-	Application No.	Applicant(s)				
	09/810,501	PAUL ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Donna C. Wortman, Ph.D.	1648				
The MAILING DATE of this communication ap						
Period for Reply	• .					
A SHORTENED STATUTORY PERIOD FOR REPI THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perior - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a reply ply within the statutory minimum of thirty (3 d will apply and will expire SIX (6) MONTH: tte, cause the application to become ABAN	y be timely filed  10) days will be considered timely.  S from the mailing date of this communication.  DONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>08</u>	December 2003.					
,						
,—	- ···					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 1	11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-41 is/are pending in the application	n.					
4a) Of the above claim(s) <u>1-29 and 32-38</u> is/a	re withdrawn from considerati	on.				
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>30,31 and 39-41</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-41</u> are subject to restriction and/o	r election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examir	ner.					
10) The drawing(s) filed on is/are: a) □ ac	ccepted or b) objected to by	the Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the corre						
11) The oath or declaration is objected to by the	Examiner. Note the attached (	Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C. § 1	19(a)-(d) or (f).				
a) All b) Some * c) None of:						
<ol> <li>Certified copies of the priority docume</li> </ol>	nts have been received.					
<ol><li>Certified copies of the priority docume</li></ol>						
3. Copies of the certified copies of the pr		eceived in this National Stage				
application from the International Bure						
* See the attached detailed Office action for a li	st of the certified copies not re	eceived.				
Attachment(s)						
1) Notice of References Cited (PTO-892)		mmary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		Mail Date  brmal Patent Application (PTO-152)				
<ol> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/C Paper No(s)/Mail Date</li> </ol>	6) Other:					

Art Unit: 1648

Claim 30 was amended and claim 41 was added in the paper filed 08 December 2003. Claims 30, 31, and 39-41 are under examination.

Claims 1-29 and 32-38 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the paper filed 31 May 2002.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 41 is rejected under 35 U.S.C. 112, second paragraph, as failing to set forth the subject matter which applicants regard as their invention. Evidence that claim 41 fails to correspond in scope with that which applicants regard as the invention can be found in the response filed 08 December 2003. In that paper, at page 9, third paragraph, applicant has stated that the recited pairs of primers are "SEQ ID NOS 1 and 2, 3 and 4, 8 and 9, 9 and 10 and 11 and 12," and this statement indicates that the invention is different from what is defined in the claim(s) because claim 41 recites "SEQ ID NOS:8 and 9, SEQ ID NOS:9 and 10, and SEQ ID NOS:11 and 12."

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 30, 31, 39 and 40 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The

Art Unit: 1648

claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

Claims 30 and 31 encompass a genus of primers that selectively amplify a North American strain of PRRSV but not the European Lelystad virus. The specification discloses no primers that actually have the required property, but only the desired function of such primers. Claims 39 and 40 encompass a genus of primers that hybridize with both Applicant's lowa virus strains and Lelystad virus. The specification describes only five primers, used as three sets of two primers each, that have the required characteristics, i.e., that hybridize with both a North American and a European PRRSV strain. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 19 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the

Art Unit: 1648

genus. Satisfactory disclosure of a "representative number" depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed. Since no primers are described that fall within the subject matter of claims 30 and 31, these claims do not comply with the written description requirement. With respect to claims 39 and 40, since the three pairs of primers disclosed correspond to only a limited region of the PRRSV genome, only the pairs of primers recited in claim 41 comply with the written description requirement.

Applicant's arguments filed 08 December 2003 have been fully considered but they are not persuasive. Applicant has argued that claim 30 as presently amended is described at page 41 of the specification, and that claim 39 is described at page 88-89 of the specification.

It is not agreed that page 41 provides written description for a representative number of species of primers that selectively amplify a North American PRRSV strain but not a European strain by actual reduction to practice; rather, it describes only the desired features of such primers but no actual primers. It is not agreed that the three pairs of primers, actually only five different primers, disclosed at page 88-89, make up a representative number of species of the genus of primers that identify both the lowa strain and the Lelystad strain, since they correspond to only a very limited portion of the viral genome.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**.

**Art Unit: 1648** 

See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

This application contains claims 1-29 and 32-38 drawn to an invention nonelected with traverse in the paper filed 31 May 2002. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna C. Wortman, Ph.D. whose telephone number is 571-272-0913. The examiner can normally be reached on Monday-Thursday, 7:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Donna C. Wortman, Ph.D.

Primary Examiner

Art Unit 1648

dcw